Skip to main content
. 2003 Dec;163(6):2347–2370. doi: 10.1016/S0002-9440(10)63591-2

Figure 7.

Figure 7.

Analysis of mRNA of cynomolgus monkey PBMC before and after infection with EBOV-Zaire. Representative RNase protection assays are shown. A: Chemokines. Comparison of preinfection PBMC (lanes A, D, F, J, M, P, T) with PBMC at postinfection day 1 (lanes B, E, G); day 2 (lanes H, N, R); day 3 (lanes C, I, K, O); day 4 (lanes L and Q); day 5 (lane U); and day 6 (lane S). B: IL-6. Comparison of preinfection PBMC (lanes A, D, F, I, L, P, R, T, V, X) with PBMC at postinfection day 1 (lanes B and G); day 2 (lanes C, E, J, M); day 3 (lanes H and K); day 4 (lanes N, Q, S); day 5 (lanes U and W); and day 6 (lanes O and Y). C: TNF-α. Comparison of preinfection PBMC (lanes A, C, F, H, K, N, R, T, V, X, Z) with PBMC at postinfection day 1 (lanes B, D, I); day 2 (lanes E, G, L, O); day 3 (lanes J and M); day 4 (lanes P, S, V); day 5 (lanes W and Y); and day 6 (lanes Q and a). D: IP-10. Comparison of PBMC at postinfection day 1 (lane A), day 3 (lane B), day 4 (lane C), day 5 (lane D) and day 6 (lane E).

HHS Vulnerability Disclosure